anti retroviral agents

Summary

Summary: Agents used to treat RETROVIRIDAE INFECTIONS.

Top Publications

  1. ncbi The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
    Charles F Gilks
    Department of HIV AIDS, World Health Organization, Geneva 1211, Switzerland
    Lancet 368:505-10. 2006
  2. ncbi Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control
    Stephen D Lawn
    Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, South Africa
    AIDS 20:1605-12. 2006
  3. pmc Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review
    Sydney Rosen
    Center for International Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 4:e298. 2007
  4. pmc Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
    Rami Kantor
    Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
    PLoS Med 2:e112. 2005
  5. ncbi Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy
    Guillaume Breton
    Department of Infectious and Tropical Diseases, INSERM E0357, Bichat Claude Bernard Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Clin Infect Dis 39:1709-12. 2004
  6. pmc The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
    Jonathan E Golub
    Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland 21231, USA
    AIDS 21:1441-8. 2007
  7. pmc Expanding access to antiretroviral therapy in sub-saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities
    David McCoy
    Health Systems Trust, PO Box 808, Durban 4000, South Africa
    Am J Public Health 95:18-22. 2005
  8. ncbi Class of antiretroviral drugs and the risk of myocardial infarction
    Nina Friis-Møller
    University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 356:1723-35. 2007
  9. ncbi Scaling-up antiretroviral treatment in Southern African countries with human resource shortage: how will health systems adapt?
    Wim Van Damme
    Institute of Tropical Medicine, Department of Public Health, Nationalestraat 155, 2000 Antwerp, Belgium
    Soc Sci Med 66:2108-21. 2008
  10. pmc Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique
    Cynthia R Pearson
    Department of Psychology, University of Washington, Seattle, WA 98195 1525, USA
    J Acquir Immune Defic Syndr 46:238-44. 2007

Detail Information

Publications237 found, 100 shown here

  1. ncbi The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
    Charles F Gilks
    Department of HIV AIDS, World Health Organization, Geneva 1211, Switzerland
    Lancet 368:505-10. 2006
    ..Simplified operational guidelines, tools, and training materials enable clinical teams in primary-care and second-level facilities to deliver HIV prevention, HIV care, and ART, and to use a standardised patient-tracking system...
  2. ncbi Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control
    Stephen D Lawn
    Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, South Africa
    AIDS 20:1605-12. 2006
    ..To determine burden and risk factors for tuberculosis (TB) in an antiretroviral treatment (ART) programme and its impact on ART outcomes...
  3. pmc Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review
    Sydney Rosen
    Center for International Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 4:e298. 2007
    ..In this paper we present a systematic review of patient retention in ART programs in sub-Saharan Africa...
  4. pmc Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
    Rami Kantor
    Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
    PLoS Med 2:e112. 2005
    ..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate...
  5. ncbi Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy
    Guillaume Breton
    Department of Infectious and Tropical Diseases, INSERM E0357, Bichat Claude Bernard Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Clin Infect Dis 39:1709-12. 2004
    ..These results have implications for the diagnosis of IRIS and the understanding of its pathogenesis...
  6. pmc The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
    Jonathan E Golub
    Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland 21231, USA
    AIDS 21:1441-8. 2007
    ..Antiretroviral therapy (ART) lowers the risk of tuberculosis, but may not be sufficient to control HIV-related tuberculosis. Isoniazid preventive therapy (IPT) reduces tuberculosis incidence significantly, but is not widely used...
  7. pmc Expanding access to antiretroviral therapy in sub-saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities
    David McCoy
    Health Systems Trust, PO Box 808, Durban 4000, South Africa
    Am J Public Health 95:18-22. 2005
    ....
  8. ncbi Class of antiretroviral drugs and the risk of myocardial infarction
    Nina Friis-Møller
    University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 356:1723-35. 2007
    ..We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction...
  9. ncbi Scaling-up antiretroviral treatment in Southern African countries with human resource shortage: how will health systems adapt?
    Wim Van Damme
    Institute of Tropical Medicine, Department of Public Health, Nationalestraat 155, 2000 Antwerp, Belgium
    Soc Sci Med 66:2108-21. 2008
    ..The latter two scenarios would entail a high degree of de-medicalisation of ART...
  10. pmc Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique
    Cynthia R Pearson
    Department of Psychology, University of Washington, Seattle, WA 98195 1525, USA
    J Acquir Immune Defic Syndr 46:238-44. 2007
    ..To assess the efficacy of a peer-delivered intervention to promote short-term (6-month) and long-term (12-month) adherence to HAART in a Mozambican clinic population...
  11. ncbi Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda
    Jane Wanyama
    Infectious Disease Institute, Kampala, Uganda
    AIDS 21:1486-7. 2007
    ....
  12. ncbi Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda
    Rebecca Bunnell
    CDC Uganda, Global AIDS Program, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
    AIDS 20:85-92. 2006
    ..The impact of antiretroviral therapy (ART) on sexual risk behavior and HIV transmission among HIV-infected persons in Africa is unknown...
  13. ncbi Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care
    Lytt I Gardner
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS 19:423-31. 2005
    ..The Antiretroviral Treatment Access Study (ARTAS) assessed a case management intervention to improve linkage to care for persons recently receiving an HIV diagnosis...
  14. ncbi High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda
    Johan van Griensven
    Medecins Sans Frontieres, Kimihurura, Kacyiru, 1361 Kigali, Rwanda
    Trans R Soc Trop Med Hyg 101:793-8. 2007
    ..Lipoatrophy appears to be an important long-term complication of WHO-recommended first-line ART regimens. These data highlight the urgent need for access to more affordable and less toxic ART regimens in resource-limited settings...
  15. ncbi Cardiovascular risk and body-fat abnormalities in HIV-infected adults
    Steven Grinspoon
    Program in Nutritional Metabolism and the Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 352:48-62. 2005
  16. ncbi Combination antiretroviral therapy and the risk of myocardial infarction
    Nina Friis-Møller
    N Engl J Med 349:1993-2003. 2003
    ..It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction...
  17. ncbi HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population
    Charlotte Lewden
    INSERM, U593, Bordeaux, France
    J Acquir Immune Defic Syndr 46:72-7. 2007
    ..To compare mortality rates in combination antiretroviral therapy (cART)-treated HIV-infected adults with mortality in the general population according to the level of CD4 cell count reached and the duration of exposure to cART...
  18. pmc Treatment outcomes of patients with HIV and tuberculosis
    Payam Nahid
    University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, 5K1, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 175:1199-206. 2007
    ..The optimal length of tuberculosis treatment in patients coinfected with HIV is unknown...
  19. pmc Effect of early versus deferred antiretroviral therapy for HIV on survival
    Mari M Kitahata
    University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359931, Seattle, WA 98104, USA
    N Engl J Med 360:1815-26. 2009
    ..The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain...
  20. ncbi Community health workers as a cornerstone for integrating HIV and primary healthcare
    J S Mukherjee
    Harvard Medical School, Boston, MA 02115, USA
    AIDS Care 19:S73-82. 2007
    ..The results of this study will be used to emphasize, standardized and strengthen the biosocial training of CHWs...
  21. ncbi Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era
    A Phillips
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    AIDS 18:51-8. 2004
    ..e., pre-September 1995), especially in those with CD4 cell count > 200 x 10 cells/l, is lacking...
  22. pmc Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
    P Mugyenyi
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 375:123-31. 2010
    ..This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term effect on clinical outcomes in Africa...
  23. pmc Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations
    Yumi Mitsuya
    Department of Medicine, Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    J Virol 82:10747-55. 2008
    ....
  24. pmc Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru
    Walter H Curioso
    School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru
    BMC Med Inform Decis Mak 7:24. 2007
    ..The purpose of this paper is to report on perceptions towards use of information and communication technologies as a means to support antiretroviral medication adherence and HIV transmission risk reduction...
  25. ncbi Missed opportunities to address reproductive health care needs among HIV-infected women in antiretroviral therapy programmes
    Landon Myer
    Infectious Diseases Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, South Africa
    Trop Med Int Health 12:1484-9. 2007
    ..To investigate the delivery of reproductive health care services in an antiretroviral therapy (ART) programme in Cape Town, South Africa...
  26. pmc Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration
    Mary Ann Davies
    School of Public Health and Family Medicine, University of Cape Town
    S Afr Med J 99:730-7. 2009
    ..To assess paediatric antiretroviral treatment (ART) outcomes and their associations from a collaborative cohort representing 20% of the South African national treatment programme...
  27. ncbi Defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia
    Kebede Deribe
    Jimma University Faculty Of Public Health Department Of General Public Health, Jimma, Ethiopia
    Trop Med Int Health 13:328-33. 2008
    ..To determine the prevalence of and factors associated with defaulting from antiretroviral treatment (ART) in Jimma, Ethiopia...
  28. ncbi Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
    ..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
  29. pmc Human cytidine deaminase APOBEC3H restricts HIV-1 replication
    Ying Dang
    Department of Microbiology and Molecular Genetics, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan 48824 4320, USA
    J Biol Chem 283:11606-14. 2008
    ..Thus, A3H inhibits HIV-1 replication potently by a cytidine deamination-independent mechanism, and optimizing A3H expression in vivo should represent a novel therapeutic strategy for HIV-1 treatment...
  30. ncbi Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited
    Catherine Orrell
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
    Antivir Ther 12:83-8. 2007
    ....
  31. pmc Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings
    Mathieu Forster
    Institute of Social and Preventive Medicine, University of Bern, Switzerland
    Bull World Health Organ 86:939-47. 2008
    ....
  32. pmc Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants
    Siaka Toure
    Aconda Association, Abidjan, Cote d Ivoire
    AIDS 22:873-82. 2008
    ..To assess the rates and determinants of mortality, loss to follow-up and immunological failure in a nongovernmental organization-implemented program of access to antiretroviral treatment in Côte d'Ivoire...
  33. ncbi Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities
    Robert H Remien
    HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, NY 10036, USA
    AIDS Behav 7:61-72. 2003
    ..g., cognitive, emotional, interpersonal) can have compensatory influences on behavioral outcomes. Findings are discussed in terms of social action theory, contributing to our theoretical understanding of the phenomenon of adherence...
  34. ncbi Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
    Neel R Gandhi
    AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    Lancet 368:1575-80. 2006
    ..We assessed the prevalence and consequences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in a rural area in KwaZulu Natal, South Africa...
  35. pmc Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management
    Jane M Simoni
    Department of Psychology, University of Washington, Seattle, Washington, 98195 1525, Box 351525, USA
    AIDS Behav 10:227-45. 2006
    ..We conclude that even brief self-report measures of antiretroviral adherence can be robust, and recommend items and strategies for HIV research and clinical management...
  36. pmc Posterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome
    Alay S Banker
    Banker s Retina Clinic and Laser Centre, 5 Subhash Society, Behind Ishvar Bhuvan, Ahmedabad 380 009, India
    Indian J Ophthalmol 56:377-83. 2008
    ..Immune recovery uveitis is a new cause of vision loss in patients on HAART. Diagnosis and treatment are guided by the particular conditions and immune status of the patient...
  37. ncbi HIV prevention for a threatened continent: implementing positive prevention in Africa
    Rebecca Bunnell
    Centers for Disease Control and Prevention Uganda, Global AIDS Program, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Entebbe, Uganda
    JAMA 296:855-8. 2006
  38. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
    ..Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere...
  39. ncbi The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world
    Bernhard Schwartlander
    The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
    Lancet 368:541-6. 2006
  40. ncbi Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya
    Kara Wools-Kaloustian
    Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    AIDS 20:41-8. 2006
    ..To determine the clinical and immunological outcomes of a cohort of HIV-infected patients receiving antiretroviral therapy...
  41. ncbi Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda
    David Moore
    Global AIDS Program, Us centers for Disease Control and Prevention CDC, Entebbe, Uganda
    AIDS 21:713-9. 2007
    ..Tuberculosis (TB) is the leading cause of death among people with HIV in sub-Saharan Africa. Expanding access to antiretroviral therapy (ART) may reduce the burden of TB, but to what extent is unknown...
  42. pmc TRIM E3 ligases interfere with early and late stages of the retroviral life cycle
    Pradeep D Uchil
    Section of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, United States of America
    PLoS Pathog 4:e16. 2008
    ..In contrast, downregulation of TRIM11 and 15 enhanced virus release suggesting that these proteins contribute to the endogenous restriction of retroviruses in cells...
  43. ncbi The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models
    Sally Blower
    AIDS 19:1-14. 2005
    ..Instead, we recommend that patients should be closely monitored for acquired resistance, and sentinel surveillance (in a few urban centers) should be used to monitor transmitted resistance...
  44. pmc Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators
    Dennis Ross-Degnan
    Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston MA, USA
    BMC Health Serv Res 10:42. 2010
    ..Access to antiretroviral therapy has dramatically expanded in Africa in recent years, but there are no validated approaches to measure treatment adherence in these settings...
  45. ncbi Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection
    Hendrik Streeck
    Partners AIDS Research Center, Infectious Disease Unit, Massachusetts General Hospital, Charlestown, MA, 02129, USA
    J Infect Dis 194:734-9. 2006
    ..However, despite these immunological changes, no differences in viremia or in the CD4+ T cell count were found 6 months after HAART was stopped, when treated subjects were compared with untreated subjects...
  46. pmc Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells
    Hendrik Streeck
    Partners AIDS Research Center, Infectious Disease Unit, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 5:e100. 2008
    ....
  47. ncbi Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, and Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    AIDS 23:1875-80. 2009
    ..To assess the utility of urine lipoarabinomannan (LAM) detection as a diagnostic screening test for tuberculosis (TB) in HIV-infected patients with advanced immuno deficiency and high prevalence of sputum smear-negative pulmonary disease...
  48. ncbi Fighting HIV--lessons from Brazil
    Susan Okie
    N Engl J Med 354:1977-81. 2006
  49. ncbi Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia
    Yonas Tadios
    Department of Community Health, Faculty of Medicine, Addis Ababa University
    Ethiop Med J 44:237-44. 2006
    ..To assess the degree of adherence with highly active antiretroviral therapy (HAART), and its correlates among adults with HIV/AIDS in Addis Ababa...
  50. ncbi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  51. pmc Predictors of antiretroviral treatment failure in an urban HIV clinic
    Gregory K Robbins
    Division of Infectious Diseases, Massachusetts General Hospital, Harvard Center for AIDS Research CFAR, and Harvard Medical School, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 44:30-7. 2007
    ..Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations...
  52. ncbi Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort
    Sophie Matheron
    Service des Maladies Infectieuses et Tropicales A, Hopital Bichat Claude Bernard, Assistance Publique des Hopitaux de Paris, France
    AIDS 17:2593-601. 2003
    ..To identify factors associated with clinical progression in HIV-2 infected patients...
  53. pmc Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities
    Marc Andre Langlois
    Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry Hills Road, Cambridge CB2 2QH, UK
    Nucleic Acids Res 33:1913-23. 2005
    ..The approach has allowed the isolation of APOBEC3 DNA mutators that exhibit novel target site preferences...
  54. ncbi Examining the production costs of antiretroviral drugs
    Eloan Pinheiro
    Department of HIV AIDS, World Health Organization, Geneva, Switzerland
    AIDS 20:1745-52. 2006
    ....
  55. ncbi Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya
    Heiko Karcher
    Institute of Tropical Medicine and International Health, Charite University Medicine Berlin, Germany
    Trop Med Int Health 12:687-94. 2007
    ..To evaluate risk factors for treatment denial and loss to follow-up in an antiretroviral treatment (ART) cohort in a rural African setting in western Kenya...
  56. ncbi Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care
    Martha Bedelu
    Medecins Sans Frontieres, Lusikisiki, South Africa
    J Infect Dis 196:S464-8. 2007
    ..Maintaining quality and coverage will require increased resource input from the public sector and full acceptance of creative approaches to implementation, including task shifting and community involvement...
  57. ncbi Effect of a brief antiretroviral adherence intervention delivered by HIV care providers
    Joel Milam
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Acquir Immune Defic Syndr 40:356-63. 2005
    ..More intensive intervention is needed to improve adherence among patients who are initially less than 95% adherent...
  58. ncbi Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lancet 364:51-62. 2004
    ..We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure...
  59. ncbi Effectiveness of antiretroviral treatment in a South African program: a cohort study
    Lara R Fairall
    Knowledge Translation Unit, University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa
    Arch Intern Med 168:86-93. 2008
    ....
  60. pmc Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection
    Vikram S Gill
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Clin Infect Dis 50:98-105. 2010
    ....
  61. ncbi APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein
    Timothy M Alce
    Oncology Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    J Biol Chem 279:34083-6. 2004
    ..Binding to the NC domain would ensure that APOBEC3G will be concentrated in the viral core of mature HIV-1, in close proximity to the reverse transcription complex...
  62. ncbi Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 43:770-6. 2006
    ..Understanding the determinants of key outcome measures--including death and nondeath losses--would assist in program evaluation and development...
  63. ncbi The impact of HIV treatment on risk behaviour in developing countries: a systematic review
    C Kennedy
    Johns Hopkins Bloomberg School of Public Health, Department of International Health, Baltimore, Maryland, USA
    AIDS Care 19:707-20. 2007
    ..However, there are few existing studies and the rigor of these studies is weak. More studies are needed to build an evidence base on which to make programmatic and policy decisions...
  64. pmc Modelling the impact of antiretroviral use in resource-poor settings
    Rebecca F Baggaley
    Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom
    PLoS Med 3:e124. 2006
    ..Mathematical models can explore the potential impacts of various treatment strategies, including timing of treatment initiation and provision of laboratory monitoring facilities, to complement evidence from pilot programmes...
  65. ncbi Fair process in patient selection for antiretroviral treatment in WHO's goal of 3 by 5
    Norman Daniels
    Harvard School of Public Health, Boston, MA 02115, USA
    Lancet 366:169-71. 2005
  66. pmc Anterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome
    Jyotirmay Biswas
    Sankara Nethralaya, 18, College Road, Chennai 600 006, India
    Indian J Ophthalmol 56:363-75. 2008
    ..This article is a comprehensive update of the important anterior segment and adnexal manifestations in HIV-positive patients with special reference to their prevalence in the Indian population...
  67. ncbi Antiretroviral treatment for children
    Brian Eley
    Red Cross War Memorial Children s Hospital, Rondebosch, Cape Town, South Africa
    S Afr Med J 96:988-93. 2006
    ..To describe the response of children during their first year on highly active antiretroviral therapy (HAART)...
  68. ncbi Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand
    Marc Lallemant
    Epidémiologie Clinique, Santé Maternelle et Infantile et Sida, Institut de Recherche pour le Développement, Paris
    N Engl J Med 351:217-28. 2004
    ..We hypothesized that the administration, in addition to zidovudine, of a single dose of oral nevirapine to mothers during labor and to neonates would further reduce transmission of HIV...
  69. pmc Access to antiretroviral treatment in Africa
    Rene Loewenson
    BMJ 328:241-2. 2004
  70. ncbi Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study
    M Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    HIV Med 9:397-405. 2008
    ..To investigate delayed HIV diagnosis and late initiation of antiretroviral therapy (ART) in the Swiss HIV Cohort Study...
  71. pmc Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators
    John C Chalker
    Center for Pharmaceutical Management, Management Sciences for Health, Arlington Virginia, USA
    BMC Health Serv Res 10:43. 2010
    ..We evaluated the feasibility of collecting routine data to standardize adherence measurement using a draft set of indicators...
  72. pmc Introduction and immunopathogenesis of acquired immune deficiency syndrome
    S Sudharshan
    Medical and Vision Research Foundations, Sankara Nethralaya, 18, College Road, Chennai 600 006, Tamil Nadu, India
    Indian J Ophthalmol 56:357-62. 2008
    ..Advent of highly active antiretroviral treatment (HAART) has revolutionized the management of AIDS though there is associated increased development of immune recovery uveitis in a few of these patients...
  73. ncbi Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy
    Weerawat Manosuthi
    Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Tiwanon Road, Nonthaburi 11000, Thailand
    J Infect 53:357-63. 2006
    ..To determine the frequency, risk factors and mortality rate of immune reconstitution inflammatory syndrome (IRIS) of tuberculosis (TB) in patients co-infected with HIV/TB and receiving antiretroviral therapy (ART)...
  74. ncbi Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications
    Jean B Nachega
    Department of International Health, Global Disease Epidemiology and Control Program, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Suite W5031, Baltimore, MD 21205, USA
    Curr HIV/AIDS Rep 6:121-9. 2009
    ..In this article, we review the effects of these metabolic complications on ART adherence and approaches to prevent or reverse them...
  75. ncbi The real challenges for scaling up ART in sub-Saharan Africa
    Wim Van Damme
    AIDS 20:653-6. 2006
  76. ncbi Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study
    David M Murdoch
    Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina NC 27710, USA
    AIDS 22:601-10. 2008
    ..To determine the incidence, clinical manifestations, risk factors and outcome of immune reconstitution inflammatory syndrome (IRIS) in South Africa...
  77. pmc Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial
    Andrew Zolopa
    Stanford University AIDS Clinical Trials Unit, Stanford University, Stanford, California, United States of America
    PLoS ONE 4:e5575. 2009
    ..Optimal timing of ART initiation for individuals presenting with AIDS-related OIs has not been defined...
  78. ncbi Antiretroviral therapy in a thousand patients with AIDS in Haiti
    Patrice Severe
    Groupe Haitien d Etude du Sarcome de Kaposi et des Infections Opportunistes, Port au Prince, Haiti
    N Engl J Med 353:2325-34. 2005
    ..High rates of coinfection with tropical diseases and tuberculosis, along with malnutrition and limited laboratory monitoring of therapy, may decrease the efficacy of antiretroviral therapy in these countries...
  79. pmc Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, United States of America
    PLoS Med 3:e484. 2006
    ..Reconstitution in the peripheral blood during therapy with highly active antiretroviral therapy (HAART) is well established. However, the extent of immune reconstitution in the GI tract is unknown...
  80. ncbi Home-based antiretroviral care is associated with positive social outcomes in a prospective cohort in Uganda
    Rose Apondi
    CDC Uganda, Global AIDS Program, Entebbe, Uganda
    J Acquir Immune Defic Syndr 44:71-6. 2007
    ..Home-based antiretroviral therapy (ART) care in Africa has expanded; but social outcomes of home-based ART programs are unknown...
  81. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  82. ncbi Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS
    Jeffrey S Gonzalez
    Department of Psychology, University of Miami, Miami, FL 33134, USA
    Health Psychol 23:413-8. 2004
    ..PSOM partially mediated the relationship between social support and adherence. PSOM may be an important mechanism through which social support is related to better medication adherence in this population...
  83. ncbi Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy
    M Maskew
    Clinical HIV Research Unit, Department of Medicine, University of the Witwatersrand
    S Afr Med J 97:853-7. 2007
    ..Data on a sample of patients who failed to return for follow-up were analysed to identify the causes and to plan strategies to overcome the problem...
  84. ncbi Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA
    Miguel Goicoechea
    Department of Medicine, University of California, San Diego, Antiviral Antiviral Research Center, 92131
    J Infect Dis 194:29-37. 2006
    ..Suboptimal CD4+ T cell recovery during antiretroviral therapy (ART) is a common clinical dilemma...
  85. ncbi Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector
    Gregory P Bisson
    Division of Infectious Disease, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    AIDS 20:1333-6. 2006
    ..001]. HAART costs should be minimized as scale-up efforts in sub-Saharan Africa progress...
  86. pmc Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic
    David Heiden
    Department of Ophthalmology and Pacific Vision Foundation, California Pacific Medical Center, San Francisco, California, United States of America
    PLoS Med 4:e334. 2007
  87. ncbi Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya
    Claudia Hawkins
    Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA, and Department of Medicine, Saint Mary s Mission Hospital, Nairobi, Kenya
    J Acquir Immune Defic Syndr 45:304-10. 2007
    ..Insufficient data exist on the durability and tolerability of first-line antiretroviral therapy (ART) regimens provided by HIV treatment programs implemented in developing countries...
  88. ncbi Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi
    Rony Zachariah
    Medecins Sans Frontieres, Operational Research, Brussels Operational Center, Belgium
    AIDS 20:2355-60. 2006
    ....
  89. pmc HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?
    Colleen V Chien
    Fenwick and West LLP, Oakland, California, United States of America
    PLoS ONE 2:e278. 2007
    ..This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs...
  90. ncbi Scaling up antiretroviral treatment in resource-poor settings
    Anthony D Harries
    Ministry of Health, Lilongwe, Malawi
    Lancet 367:1870-2. 2006
  91. pmc IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates
    Louis J Picker
    Vaccine and Gene Therapy Institute, Department of Pathology, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon 97006, USA
    J Clin Invest 116:1514-24. 2006
    ....
  92. ncbi Scaling up access to antiretroviral treatment in southern Africa: who will do the job?
    Katharina Kober
    Institute of Tropical Medicine, Department of Public Health, Antwerp, Belgium
    Lancet 364:103-7. 2004
    ..Yet, none of the countries has developed an urgently required comprehensive human resource strategy. This may also need increased donor attention and resources...
  93. ncbi Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi
    David J Bell
    Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
    J Acquir Immune Defic Syndr 45:560-3. 2007
    ..To compare 3 measures of adherence to antiretroviral therapy (ART) in HIV-positive adults receiving free treatment from a public hospital in Malawi...
  94. pmc Adherence to antiretroviral therapy: merging the clinical and social course of AIDS
    Arachu Castro
    Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
    PLoS Med 2:e338. 2005
  95. ncbi Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa
    Sydney Rosen
    Center for International Health and Development, Boston University School of Public Health, Boston, MA 02118, USA
    Lancet 365:354-6. 2005
  96. ncbi Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival
    Cornelia Staehelin
    Division of Infectious Diseases, University Hospital Berne, Berne, Switzerland
    AIDS 17:2237-44. 2003
    ....
  97. ncbi Curing stigma--the limits of antiretroviral access
    Oni Blackstock
    Montefiore Medical Center, New York, USA
    N Engl J Med 353:752. 2005
  98. ncbi Antiretroviral programme in rural Uganda
    Christopher J Gill
    Center for International Health and Development, Boston University School of Public Health, Boston, MA 02118, USA
    Lancet 368:1556-7. 2006
  99. pmc "That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme
    Mison Dahab
    Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    BMC Public Health 8:63. 2008
    ..This qualitative study examines potential barriers to, and facilitators of, adherence to ART in a workplace programme in South Africa...

Research Grants63

  1. Study of zidovudine addition in HIV-associated neurocognitive disorders
    Albert Anderson; Fiscal Year: 2013
    ..Overall, this career development project will allow the principal investigator to pursue the goal o becoming an established investigator and leader in HIV CNS research. ..
  2. Pharmacology of Antiretroviral Nanoparticle Micelles
    Christopher J Destache; Fiscal Year: 2010
    ..Due to the nanoparticle small size, the particles will stay in tissue longer and allow for less frequent dosing. This nanoparticle delivery system could affect the future of HIV- 1 treatment. ..
  3. Development of Transdermal Films for the the Delivery of HIV Therapeutics
    Anthony Sang Won Ham; Fiscal Year: 2010
    ..The research to be performed will include development of the transdermal film and the evaluation of its ability to deliver a therapeutic amount of IQP-0410 over long periods of time. ..
  4. The Role of Mitochondrial Toxicity in Metabolic Complications of Pediatric HIV
    TANVI SHAH SHARMA; Fiscal Year: 2013
    ..We can then find ways to reduce these effects by devising interventions aimed at preventing or stopping the progression of metabolic disease. ..
  5. Cornell Clinical Trials Unit
    Roy M Gulick; Fiscal Year: 2011
    ..A major focus of the Cornell unit is community outreach and education and the Cornell Community Advisory Board is active in representing our diverse community. ADMINISTRATIVE COMPONENT: ..
  6. Cornell Clinical Trials Unit
    Roy M Gulick; Fiscal Year: 2013
    ..A major focus of the Cornell unit is community outreach and education and the Cornell Community Advisory Board is active in representing our diverse community. ADMINISTRATIVE COMPONENT: ..
  7. Sex, Aging and Antiretroviral Pharmacology
    Kristine B Patterson; Fiscal Year: 2012
    ..Moore). Relevance: The knowledge gained through this training program and from this study will be used to design studies that modulate infectivity and treatment responses through exogenous hormone supplementation. ..
  8. Ex Vivo Model for Assessing the Vaginal Disposition of PrEP Antiretrovirals
    MARC MICHAEL BAUM; Fiscal Year: 2013
    ....
  9. IMPACT OF INTESTINAL DYSFUNCTION ON ANTIRETROVIRAL THERAPY IN INDIA
    RITA CAROLINE ISAAC; Fiscal Year: 2012
    ....
  10. Role of proBDNF and p75NTR in HIV-mediated axonal/dendritic degeneration
    Italo Mocchetti; Fiscal Year: 2013
    ..We expect to provide new significant data on the role of p75NTR in HIV neurotoxicity. These data will help in the design of p75NTR antagonists as an adjunct therapy against synaptic simplification caused by HIV. ..
  11. Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions
    AWEWURA JACOB KWARA; Fiscal Year: 2010
    ....
  12. Endogenous retroviruses and gene regulation after injury
    Kiho Cho; Fiscal Year: 2010
    ..Furthermore, the findings from this study may lead to a further investigation into the development of a novel therapeutic protocol for burn patients in combination with current regimens. ..
  13. Persistence of CNS T. pallidum in HIV Infection
    Christina M Marra; Fiscal Year: 2012
    ..Our proposed research builds on our previous work and will lead to ways to better diagnose and treat neurosyphilis. ..
  14. REPRODUCTIVE ASSESSMENTS BY CONTINUOIUS BREEDING (RACB)
    Rochelle Tyl; Fiscal Year: 2013
    ..The study has progressed through production of first- and second-generation offspring, and detailed evaluation of those offspring and analysis of the data is in process. ..
  15. REPRODUCTIVE ASSESSMENTS BY CONTINUOIUS BREEDING (RACB)
    Rochelle W Tyl; Fiscal Year: 2009
    ..The study has progressed through production of first- and second-generation offspring, and detailed evaluation of those offspring and analysis of the data is in process. ..
  16. Development and Evaluation of Dual Compartment Combination Microbicides
    ROBERT WALTER BUCKHEIT; Fiscal Year: 2013
    ..Through our industrial partnership with ImQuest Pharmaceuticals our methodology and products will have an immediate outlet to further clinical development. ..
  17. Antiretroviral-Induced Defects in Muscle Protein Synthesis
    Charles H Lang; Fiscal Year: 2010
    ..Such data is needed to both realize the full potential and avoid possible pitfalls of this drug in the long-term treatment of HIV-infected individuals. ..
  18. Characterizing a small molecule of Streptococcus cristatus for HIV drug design
    Bindong Liu; Fiscal Year: 2013
    ..This study will yield valuable information for developing novel anti-AIDS drug, eventually providing new weapons to fight HIV/AIDS. ..
  19. Impact of HIV-1 Tat protein on cocaine-dopamine transporter interaction
    Jun Zhu; Fiscal Year: 2013
    ....
  20. HIV DART: Frontiers in Drug Development for Antiretroviral Therapies
    RAYMOND FELIX SCHINAZI; Fiscal Year: 2013
    ..HIV DART provides accredited Continuing Medical Education training for physicians, ensuring a lasting and positive public health impact on treatment of HIV throughout the world. ..
  21. Management of HIV as a Chronic Disease
    Douglas K Owens; Fiscal Year: 2013
    ....
  22. A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP
    MARTIN H MARKOWITZ; Fiscal Year: 2013
    ....
  23. HIV-1 capsid assembly intermediates: cellular factors and links to pathogenesis
    Jaisri R Lingappa; Fiscal Year: 2013
    ....
  24. Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
    Priscilla Y Hsue; Fiscal Year: 2012
    ..abstract_text> ..
  25. Intravaginal ring delivery of tenofovir and emtricitabine
    Thomas J Smith; Fiscal Year: 2012
    ..As the developers of the only FDA approved antiviral delivery device we believe we are uniquely qualified to develop such a product. ..
  26. Nanoparticle microbicides for delivery of combination antiretroviral drugs
    Kim A Woodrow; Fiscal Year: 2012
    ..The outcomes from our proposed research may highly impact the field of microbicide research for HIV and other sexually-transmitted infections. ..
  27. Nanoparticle microbicides for delivery of combination antiretroviral drugs
    Kim A Woodrow; Fiscal Year: 2013
    ..The outcomes from our proposed research may highly impact the field of microbicide research for HIV and other sexually-transmitted infections. ..
  28. Enhancing control of HIV by inhibiting TRAILshort
    Andrew D Badley; Fiscal Year: 2013
    ..In this regard, we have additional preliminary data indicating that inhibiting TRAILs achieves the goal of increasing killing of HIV infected T-cells, and enhancing both CTL and NK cell killing of target cells. ..
  29. NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY
    RAYMOND SCHINAZI; Fiscal Year: 2009
    ..abstract_text> ..
  30. ALKALOID SYNTHESIS VIA (3+2) CYCLOADDITIONS
    BRIAN COPPOLA; Fiscal Year: 2003
    ..Tandem processes that involve the combination of (3+2) cycloaddition followed by additional reactions that lead to a second or third ring formation or a rearrangement are also being studied. ..
  31. Vaginal ring formulation of tenofovir microbicide
    Thomas J Smith; Fiscal Year: 2010
    ..The broad long term goal of this project is to empower women to protect themselves from HIV infection through the development of an improved microbicide based on the sustained release drug delivery of the antiretroviral agent tenofovir. ..
  32. Microbicide intravaginal ring IND enabling studies
    Thomas J Smith; Fiscal Year: 2013
    ..The milestone defining successful completion of this work will be the granting of IND No 114173 to enable Phase I clinical studies. ..
  33. HAART IN SCID MICE WITH HIV ENCEPHALITIS
    William Tyor; Fiscal Year: 2003
    ....
  34. Mechanisms in HIV-Tat mediated neurotoxicity
    Ronald L Schnaar; Fiscal Year: 2013
    ..The mechanisms by which this molecule interacts with cell surface receptors on neurons will be characterized. This would eventually lead to a rational design of new molecules that may block receptor action. ..
  35. Therapeutic Interventions for HIV-1 CNS Sequestration.
    Natalie Eddington; Fiscal Year: 2005
    ..Obtaining therapeutic CNS levels of anti-retroviral agents is essential to minimizing HIV-1 in the CNS. As such, this proposal offers a viable approach to address this complication of HIV/AIDS. ..
  36. Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)
    LAWRENCE JAMES D'ANGELO; Fiscal Year: 2013
    ..Finally, it will try to find ways to restore the health of youth who have become very ill as a result of this infection. ..
  37. GARLIC PREPARATIONS AND ANTIRETROVIRAL DRUGS
    David Greenblatt; Fiscal Year: 2004
    ..The work will provide immediately applicable clinical data on garlic interactions with antiretrovirals, as well as mechanistic data identifying the interaction process and its predictability from in vitro models. ..
  38. NOVEL APPROACHES TO THE DISCOVERY OF ANTI-HIV AGENTS
    Yitzhak Tor; Fiscal Year: 2007
    ..Potent and specific effectors of essential regulatory events will significantly advance the development of highly active antiretroviral agents. ..
  39. STRUCTURAL STUDIES OF A GROUP OF ACYLTRANSFERASES
    Donghai Wu; Fiscal Year: 2000
    ..Specifically, we propose to determine the structural basis of substrate recognition of these acyltransferases using a combination of biophysical and molecular genetic approaches. ..
  40. MIDCAREER INVESTIGATOR AWARD IN NEURO-AIDS RESEARCH
    David Simpson; Fiscal Year: 2005
    ..The Neuro-Adherence Program will assess the affect of neurological disease on patients' adherence to medical regimens, and the impact of education and support groups on adherence. ..
  41. Mechanisms of HIV Resistance to CCR5 Inhibitors and Consequences for Pathogenesis
    JOHN CHRISTIAN TILTON; Fiscal Year: 2010
    ....
  42. Alcohol's Effects on HIV-1 and the Blood: Brain Barrier
    Roger Pomerantz; Fiscal Year: 2004
    ..With these inter-related specific aims, it is proposed that a series of new technologies will be combined towards determining the precise effects of Etoh on inducing alterations in the BBB with HW-l I infection of these cells. ..
  43. Intravaginal ring microbicide formulations comprising multiple anti-HIV agents
    Thomas Smith; Fiscal Year: 2009
    ..We propose to utilize this platform technology to develop long-term vaginal ring formulations for the potential microbicides tenofovir and TMC-120. ..
  44. Bone Loss and Its Prevention in HIV Patients
    F Ross; Fiscal Year: 2006
    ..The mechanism by which Ritonavir, blunts RANKL-induced signaling, in OCs and their precursors; 3. If administration of Ritonavir, or GST-RANKL, will prevent and/or rescue Indinavir-induced osteoporosis. ..
  45. The effects of HIV-1 proteins on adipocyte biology
    Lisa Kosmiski; Fiscal Year: 2005
    ..These novel studies should provide further insight into the pathogenesis of the body fat changes associated with the HIV lipodystrophy syndrome. ..
  46. Dual-Tropic HIV-1 Strains and Primary Cell Infection
    RONALD COLLMAN; Fiscal Year: 2009
    ..6 primary isolate swarm. We anticipate that these studies will offer insight into pathways used by primary isolates to enter primary cells relevant to pathogenesis in vivo &entry inhibitor blocking strategies. ..
  47. MIAMI ADULT AIDS CLINICAL TRIALS GROUP, AACTG
    Margaret Fischl; Fiscal Year: 2006
    ..With a support system in place for the long-term follow-up of patients, the Miami ACTU anticipates to enroll approximately 80 patients into the ALLRT study (ACTG 5001) over a 2-year period. ..
  48. Tools for Eradicating HIV Reservoirs in the Brain: A Trojan Horse Approach
    Christine A Hrycyna; Fiscal Year: 2013
    ..We hypothesize that both administration of TH dimers alone, and co-administration with monomeric drugs, would serve to increase the level of the therapeutic agents in the brain. ..
  49. THE CNS AS A VIRAL RESERVOIR IN SIV INFECTED MACAQUES
    SHAWN O NEIL; Fiscal Year: 2002
    ..abstract_text> ..
  50. A Simple, Sensitive and Accurate HIV-1 Viral Load Test
    XING XIANG LI; Fiscal Year: 2004
    ..The successful outcome of Phase II study will lead to the commercialization of the test, which will give users a less expensive and more accurate alternative for HIV-1 viral load test. ..
  51. HIV-1 Envelope phenotype/genotype database resources
    Colombe Chappey; Fiscal Year: 2006
    ..abstract_text> ..
  52. PHOSPHONOFORMATE PRODRUGS AGAINST CNS RETROVIRUSES
    Andre Rosowsky; Fiscal Year: 1990
    ..The significance of this work lies in its potential to identify novel sustained release produrgs of PFA that will deliver the active agent to the CNS sanctuary for treatment of HIV infections of the CNS...
  53. COMBINATION GENETIC-CHEMOTHERAPEUTIC HIV1 THERAPY
    ROGER INOUYE; Fiscal Year: 2002
    ....
  54. MODULATION OF CELL-MEDIATED IMMUNE FUNCTION BY OPIATES
    PHILLIP PETERSON; Fiscal Year: 2007
    ..abstract_text> ..
  55. VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
    David Haas; Fiscal Year: 2006
    ..The proposed ACTU will not only enroll patients into ACTG clinical trials, but will provide the ACTG the ability to address important questions concerning AIDS treatment and pathogenesis. ..
  56. HIV-Infected Patients' Experiences with HCV Treatment
    Carol Bova; Fiscal Year: 2003
    ..Results of this study will also be valuable to clinicians, educators, researchers and those who develop treatment guidelines for HCV/HIV co-infected patients. ..
  57. ANTI-RETROVIRAL THERAPY AND IMMUNOMODULATION OF HIV
    ROBERT DEBS; Fiscal Year: 1992
    ..This approach may substantially improve the therapeutic index of both existing anti-AIDS therapies, as well as those now being developed...
  58. Assessing the Clinical Consequences of HIV Drug Resistance
    Richard Haubrich; Fiscal Year: 2009
    ..We will use specialized statistical techniques to define the relationship between HIV drug resistance and progression of HIV clinical disease, defined as a new AIDS infection or cancer or death. ..
  59. Preliminary Study of Safety and Efficacy of Policosanol for Dyslipidemia in HIV
    Barbara Swanson; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  60. Novel Inhibitors of HIV-1 Reverse Transcriptase
    BRYAN O HARA; Fiscal Year: 2003
    ..S. If the drug developed has a new mechanism of action, this would further expand the appropriate patient population. ..
  61. THERAPY EFFECTS ON HIV 1 POPULATION DYNAMICS IN CHILDREN
    Lisa Frenkel; Fiscal Year: 2002
    ....
  62. POLYMERICS DELIVERY SYSTEMS FOR ANTI-RETROVIRAL AGENTS
    Devinder Gill; Fiscal Year: 1990
    ..This approach of sustained site-specific delivery of drugs via biodegradable and biocompatible polymers can be extrapolated to improve the therapeutic properties of known anti-AIDS drugs...
  63. Mappicine inhibitors of HIV Ribonuclease H
    MICHAEL PARNIAK; Fiscal Year: 2003
    ..abstract_text> ..